One Health Biosensing is developing an intradermal continuous glucose monitoring system built around a microneedle sensing platform that sits in the skin without piercing it. Its design pairs a reusable battery pod with a daily disposable sensor to lower costs and reduce medical waste, while AI-enabled guidance is intended to help people with type 2 diabetes act on their glucose data. The sensor remains investigational and has not been approved or cleared by the FDA.
SenseonicsGermantown-based Senseonics develops and commercializes Eversense, an implantable continuous glucose monitoring system designed to provide real-time diabetes data through a sensor placed under the skin. Its Eversense 365 system is designed to last for up to one year, with a removable, rechargeable smart transmitter and mobile app for glucose tracking. Senseonics describes Eversense as the first and only long-term implantable CGM platform.GERMANTOWN, MD
iWel Health InciWel Health is an Exton, Pennsylvania biosensing company whose leadership brings deep experience from Pfizer, Bayer and the medical-device field. It develops continuous glucose monitoring technology for metabolic-health coaching, with particular attention to wellness users and people managing prediabetes or Type 2 diabetes.EXTON, PA
LifeScanFor more than 40 years, LifeScan has focused on helping people with diabetes manage their health through glucose-monitoring technology. Its OneTouch brand is used by more than 20 million people worldwide, while the company’s work also includes digital health solutions and hospital systems for diabetes care.MALVERN, PA
Natrium LLCAfter an ICU stay and diagnosis of diabetes insipidus, John Stallings co-founded Natrium to develop a wearable biosensor that continuously monitors sodium. Its investigational Natrium ONE patch is designed to track sodium in interstitial fluid and show clinicians the current reading, trend, and rate of change rather than relying only on periodic lab draws. Founded in 2024, the founder-led company is developing the device for high-risk clinical settings with co-founder and CTO Andrew Mancini, PhD, the architecture’s lead inventor.